Don M Benson

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH 43210 1240, USA
    Blood 120:4324-33. 2012
  2. pmc A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells
    Li Lin
    Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio 43205, USA
    Mol Cancer 9:217. 2010
  3. ncbi request reprint High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling Loving Hall, Columbus, OH 43210, USA
    Leuk Res 31:1069-75. 2007
  4. pmc IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH, USA
    Blood 118:6387-91. 2011
  5. pmc Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 51:243-51. 2010
  6. pmc Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents
    Sherry Mori
    Department of Pharmacy, The Ohio State University Comprehensive Cancer Center, OH, USA
    Hematol Oncol 30:156-62. 2012
  7. doi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
    Leuk Lymphoma 49:1893-8. 2008
  8. pmc The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Don M Benson
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 116:2286-94. 2010
  9. doi request reprint High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Eur J Haematol 81:425-31. 2008
  10. doi request reprint Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009

Detail Information

Publications35

  1. pmc A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH 43210 1240, USA
    Blood 120:4324-33. 2012
    ..These findings suggest that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM. This trial was registered at www.clinicaltrials.gov as #NCT00552396...
  2. pmc A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells
    Li Lin
    Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio 43205, USA
    Mol Cancer 9:217. 2010
    ..A novel small molecular STAT3 inhibitor, FLLL32 was specifically designed from dietary agent, curcumin to inhibit constitutive STAT3 signaling in multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells...
  3. ncbi request reprint High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling Loving Hall, Columbus, OH 43210, USA
    Leuk Res 31:1069-75. 2007
    ..BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM...
  4. pmc IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH, USA
    Blood 118:6387-91. 2011
    ..These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM...
  5. pmc Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 51:243-51. 2010
    ..Our data extrapolate on prior work and expand on ongoing controversies about optimal induction regimens for patients with MM planned for subsequent HDC/SCT and optimal sequencing of therapies...
  6. pmc Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents
    Sherry Mori
    Department of Pharmacy, The Ohio State University Comprehensive Cancer Center, OH, USA
    Hematol Oncol 30:156-62. 2012
    ..These findings suggest potentially novel roles for sFLC in patients with MM with an intact M protein receiving novel agent-based induction strategies followed by HDC/SCT...
  7. doi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
    Leuk Lymphoma 49:1893-8. 2008
    ..Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates...
  8. pmc The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Don M Benson
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 116:2286-94. 2010
    ..A phase 2 clinical trial of CT-011 in combination with lenalidomide for patients with MM should be considered...
  9. doi request reprint High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Eur J Haematol 81:425-31. 2008
    ..At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively...
  10. doi request reprint Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009
    ....
  11. pmc The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity
    Matthew A Bill
    Department of Surgery, Arthur G, James Cancer Hospital and Richard J, Solove Research Institute, The Ohio State University, 410 W, 10th Ave, Columbus, OH 43210, USA
    Mol Cancer 9:165. 2010
    ..We hypothesized this lead compound would specifically inhibit the STAT3 signaling pathway to induce apoptosis in melanoma cells...
  12. doi request reprint Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
    Shauna M Collins
    Biomedical Sciences Program, The Ohio State University, Columbus, OH, USA
    Cancer Immunol Immunother 62:1841-9. 2013
    ..Taken together, these data suggest elotuzumab may enhance NK cell function directly and confer anti-MM efficacy by means beyond ADCC alone...
  13. pmc A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells
    Li Lin
    Department of Pediatrics, Center for Childhood Cancer, The Research Institute at Nationwide Children s Hospital, Columbus, OH 43205, USA
    Int J Cancer 130:1459-69. 2012
    ..Furthermore, LLL12 significantly blocked tumor growth of MM cells in mouse model. Our results indicate that LLL12 blocks constitutive STAT3 and IL-6 induced STAT3 signaling and may be a potential therapeutic agent for MM...
  14. pmc MicroRNAs activate natural killer cells through Toll-like receptor signaling
    Shun He
    Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 121:4663-71. 2013
    ..This may be important in the normal host defense against infection and/or malignant transformation...
  15. pmc Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines
    Matthew A Bill
    Department of Internal Medicine, Division of Hematology and Oncology, 302B Comprehensive Cancer Center, Columbus, OH 43210, USA
    Mol Cancer Ther 8:2726-35. 2009
    ..These data show that although curcumin can induce apoptosis of melanoma cells, it can also adversely affect the responsiveness of immune effector cells to clinically relevant cytokines that possess antitumor properties...
  16. doi request reprint Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
    Mehdi Hamadani
    Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:547-53. 2009
    ..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy...
  17. pmc Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein
    Craig C Hofmeister
    The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 29:3427-34. 2011
    ..The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM...
  18. ncbi request reprint Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach
    Carlos Arce-Lara
    Department of Internal Medicine, Division of Hematology Oncology, Ohio State University, Columbus, Ohio 43210 1280, USA
    Urology 69:1209.e5-7. 2007
    ..We describe the clinical presentation and diagnostic and therapeutic approach to these cases, highlighting the successful preoperative use of imatinib mesylate (Gleevec) followed by prostatectomy...
  19. ncbi request reprint A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer
    Manisha H Shah
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, USA
    Clin Cancer Res 12:3993-6. 2006
    ..To determine the safety, toxicity, and immune modulation of this combination of cytokines in vivo, we conducted a first-in-man phase I study...
  20. pmc Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma
    Neil C Dunavin
    Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Leuk Lymphoma 54:1658-64. 2013
    ..037). No superiority of one agent was seen. In summary, early or late ASCT is a viable option for patients with MM receiving induction treatment with novel targeted therapies...
  21. doi request reprint The role of natural killer cells in immunity against multiple myeloma
    James Godfrey
    The Ohio State University College of Medicine, Columbus, OH, USA
    Leuk Lymphoma 53:1666-76. 2012
    ..The present review summarizes the current understanding of the NK cell versus MM effect and characterizes therapeutic interventions that exert anti-MM efficacy via NK cell function against the disease...
  22. pmc NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, USA
    J Clin Invest 121:1456-70. 2011
    ..Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia...
  23. doi request reprint Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay
    Sri Vidya Kondadasula
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Cancer Immunol Immunother 57:1137-49. 2008
    ..These studies reveal an effective method to detect ERK activation in immune cells and demonstrate that IL-2 activates ERK in a subset of NK cells and monocytes but not T cells...
  24. pmc Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells
    Don M Benson
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210 1240, USA
    Blood 113:2706-14. 2009
    ..The effect results at least in part via enhanced MAPK-mediated modulation of p27 and CDK4. Collectively the data reveal a novel mechanism by which SCF enhances cellular proliferation in combination with IL-2/15 in primary human NK cells...
  25. pmc VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine
    Eric V Yang
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Medical Center, Columbus, OH 43210, USA
    Brain Behav Immun 22:318-23. 2008
    ..The data suggest that the ability of NE to regulate the expression of VEGF is not limited to solid epithelial tumors and suggests a possible regulatory role of catecholamine stress hormones in MM progression...
  26. pmc Characterization of multiple myeloma vesicles by label-free relative quantitation
    Sean W Harshman
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, USA Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Proteomics 13:3013-29. 2013
    ..The results illustrate the first use of label-free spectral counting applied to determine relative protein abundances in EVs...
  27. pmc Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
    Flavia Pichiorri
    Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Cancer Cell 18:367-81. 2010
    ..The results suggest that these miRNAs are positive regulators of p53 and that their downregulation plays a key role in MM development...
  28. pmc CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
    Farrukh T Awan
    Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:1204-13. 2010
    ..These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies...
  29. pmc Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells
    Brian Becknell
    Medical Scientist Program, Department of Internal Medicine, College of Medicine and Public Health, The Ohio State University, Columbus, OH 43210, USA
    Blood 109:2481-7. 2007
    ..Thus, Hlx expression in activated NK cells temporally controls and limits the monokine-induced production of IFN-gamma, in part through the targeted depletion of STAT4...
  30. ncbi request reprint Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University College of Medicine and School of Public Health, Columbus, Ohio 43210, USA
    Immunity 24:575-90. 2006
    ..Collectively, our data suggest that pro- and antiinflammatory cytokine signaling reciprocally antagonize each other in an effort to prevail in the regulation of NK cell IFN-gamma production...
  31. pmc CD94 defines phenotypically and functionally distinct mouse NK cell subsets
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    J Immunol 183:4968-74. 2009
    ..Collectively, our data suggest that CD94 is an Ag that can be used to identify functionally distinct NK cell subsets in mice and could also be relevant to late-stage mouse NK cell development...
  32. ncbi request reprint A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma
    Khuda D Khan
    American Health Network Oncology Hematology, Indianapolis, Indiana, USA
    Clin Cancer Res 12:7046-53. 2006
    ..Therefore, a large, multicenter phase 2 trial to assess the effects of rIL-2 on rituximab therapy in patients with rituxumab-refractory low-grade NHL was conducted...
  33. doi request reprint The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma
    Mehdi Hamadani
    Biol Blood Marrow Transplant 14:351-2. 2008
  34. ncbi request reprint Thalidomide-induced fulminant hepatic failure
    Mehdi Hamadani
    Mayo Clin Proc 82:638. 2007
  35. ncbi request reprint Dramatic response to single-agent rituximab in a patient with intravascular lymphoma
    Nandagopal Vrindavanam
    Am J Hematol 82:1120-1. 2007